Walleye Capital’s CytomX Therapeutics CTMX Stock Holding History

Walleye Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$474K	Buy	+126,526	New	+$483K	﹤0.01%	2796
2024 Q2	–	Sell	-85,638	Closed	-$187K	–	5658
2024 Q1	$187K	Buy	+85,638	New	+$158K	﹤0.01%	4020
2022 Q2	–	Sell	-41,535	Closed	-$111K	–	2426
2022 Q1	$111K	Buy	+41,535	New	+$159K	﹤0.01%	1717
2021 Q2	–	Sell	-17,345	Closed	-$134K	–	1369
2021 Q1	$134K	Buy	+17,345	New	+$137K	0.01%	985
2020 Q1	–	Sell	-70,397	Closed	-$585K	–	1064
2019 Q4	$585K	Buy	+70,397	New	+$475K	0.04%	607

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Walleye Capital's CTMX Position: Q2 2026 in Review

Walleye Capital opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 126,526 shares worth $474K. The stake represents ﹤0.01% of the portfolio and ranks #2796 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CTMX as recently as Q1 2024.

Walleye Capital first reported a position in CTMX in Q4 2019 and has held it in 5 quarters since. The position peaked at $585K in Q4 2019. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Walleye Capital held 126,526 shares of CytomX Therapeutics worth $474K as of Q2 2026.
CytomX Therapeutics was a new Walleye Capital position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2796 holding.
Walleye Capital first reported a position in CytomX Therapeutics in Q4 2019 and has held it in 5 quarters since.
Walleye Capital's CytomX Therapeutics position peaked at $585K in Q4 2019.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.